Howell

Psoriatic arthritis (PsA) is a long-lasting inflammatory condition that affects the joints and skin in people with psoriasis (PsO). This research aims to evaluate how well the drug zasocitinib (TAK-279) works in adults with active PsA who have not previously used biologic disease-modifying antirheumatic drugs. The study is a Phase 3 clinical trial designed to compare zasocitinib against an active comparator and placebo in this patient group. Participants will receive treatment with either zasocitinib tablets, an active comparator capsule, or a matching placebo. The study includes multiple groups to assess the effects of these treatments. Participants will be followed and treated for up to 60 weeks during the study period. During the study, participants will undergo assessments to measure the percentage achieving improvement according to the American College of Rheumatology 20 (ACR20) response at 16 weeks. Researchers will monitor symptoms, joint and skin involvement, and overall safety throughout the trial. Participants will have regular visits for evaluations and will be observed for treatment effects and any side effects over the full course of the study.

Researchers are evaluating the safety and effectiveness of the Cordella™ Pulmonary Artery Sensor System in patients with heart failure classified as New York Heart Association (NYHA) Class II and III. This prospective, multi-center, open-label, randomized clinical trial includes patients who have been diagnosed and treated for heart failure for at least three months and are receiving appropriate medical therapy. The study aims to monitor pulmonary artery pressure (PAP) data to help manage heart failure and reduce hospitalizations. The trial includes five study arms: three for NYHA II patients—Treatment Arm, Active Control Arm, and Crossover Arm—and two for NYHA III patients, including a randomized sub-study to assess a clinician-directed patient self-management strategy. The Cordella PA Sensor System consists of seven components working together to measure and transmit daily PAP readings from the patient's home to healthcare providers. Patients use the myCordella™ Patient Reader to record data, which is then analyzed for clinical assessment and management. Participants will be involved in daily PAP measurements at home, holding the patient reader device against their chest for about two minutes while seated. They must have sufficient eyesight, hearing, mental capacity, and internet coverage to operate the system. Researchers will monitor safety outcomes such as device complications and sensor failures, as well as efficacy outcomes like heart failure events or cardiovascular death over up to 24 months. Regular follow-up visits are required to assess device performance, patient condition, and study outcomes.